Cisplatin ototoxicity and role of antioxidant on its prevention

References

• Astolfi L, Ghiselli S, Guaran V, et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol Rep. 2013;29(4):1285–1292.
   PubMed Web of Science ®Google Scholar
• Saladin SP, Perez PB, Cruz B, et al. A review of ototoxic medications: implications for professionals working with consumers with hearing loss. JADARA. 2015;49:1–8.
   Google Scholar
• Campbell KCM, Le Prell CG. Drug-induced ototoxicity: diagnosis and monitoring. Drug Saf. 2018;41(5):451–464.
   PubMed Web of Science ®Google Scholar
• Pearson SE, Taylor J, Patel P, et al. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review. Int J Audiol. 2019;58(11):685–695.
   PubMed Web of Science ®Google Scholar
• Rabiço-Costa D, Gil-da-Costa MJ, Barbosa JP, et al. Platinum-drugs ototoxicity in pediatric patients with brain tumors: a 10-year review. J Pediatr Hematol Oncol. 2020;42(1):e25–e31.
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Quaranta N, Marchese R, et al. The protective role of tiopronin in cisplatin ototoxicity in Wistar rats. Int J Audiol. 2004;43(8):465–470.
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Sergi B, Ferraresi A, et al. Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol. 2004;124(4):421–426.
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Paciello F, Mezzogori D, et al. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer. 2015;113(10):1434–1444.
   PubMed Web of Science ®Google Scholar
• Breglio AM, Rusheen AE, Shide ED, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8(1):1654–1659.
   PubMed Web of Science ®Google Scholar
• Cai J, Wu X, Li X, et al. Allicin protects against cisplatin-induced stria vascularis damage: possible relation to inhibition of caspase-3 and PARP-1-AIF-mediated apoptotic pathways. ORL J Otorhinolaryngol Relat Spec. 2019;81(4):202–214.
   PubMed Web of Science ®Google Scholar
• Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226(1–2):157–167.
   PubMed Web of Science ®Google Scholar
• Gentilin E, Simoni E, Candito M, et al. Cisplatin-induced ototoxicity: updates on molecular targets. Trends Mol Med. 2019;25(12):1123–1132.
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584.
   PubMed Web of Science ®Google Scholar
• Paken J, Govender CD, Pillay M, et al. Perspectives and practices of ototoxicity monitoring. S Afr J Commun Disord. 2020;19:e1–e10.
   Google Scholar
• Fetoni AR, Ruggiero A, Lucidi D, et al. Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurootol. 2016;21(4):203–211.
   PubMed Web of Science ®Google Scholar
• Frisina RD, Wheeler HE, Fossa SD, et al. comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Cin Oncol. 2016;34(23):2712–2720.
   PubMed Web of Science ®Google Scholar
• Kalyanam B, Sarala N, Azeem Mohiyuddin SM, et al. Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: a case series follow-up study. J Cancer Res Ther. 2018;14(5):1099–1104.
   PubMed Web of Science ®Google Scholar
• Langer T, Am Zehnhoff-Dinnesen A, Radtke S, et al. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458–469.
   PubMed Web of Science ®Google Scholar
• Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:588–596.
   Web of Science ®Google Scholar
• Bielefeld EC, Tanaka C, Chen GD, et al. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect. Anticancer Drugs. 2013;24(1):43–51.
   PubMed Web of Science ®Google Scholar
• Romano A, Capozza MA, Mastrangelo S, et al. Assessment and management of platinum-related ototoxicity in children treated for cancer. Cancers. 2020;12(5):1266.
   PubMed Web of Science ®Google Scholar
• Lanvers-Kaminsky C, Ciarimboli G. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin. Pharmacogenomics. 2017;18(18):1683–1695.
   PubMed Web of Science ®Google Scholar
• Lui G, Bouazza N, Denoyelle F, et al. Association between genetic polymorphisms and platinum-induced ototoxicity in children. Oncotarget. 2018;9(56):30883–30893.
   PubMedGoogle Scholar
• Rybak LP, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear. 2019;40(2):197–204.
   PubMedGoogle Scholar
• Brouwers EE, Huitema AD, Beijnen JH, et al. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol. 2008;8:7–17.
   PubMedGoogle Scholar
• Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012;30(3):300–307.
   PubMed Web of Science ®Google Scholar
• van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev. 2020;(21):CD010885.
   Google Scholar
• Astolfi L, Simoni E, Valente F, et al. Coenzyme Q10 plus multivitamin treatment prevents cisplatin ototoxicity in rats. PLOS One. 2016;11(9):e0162106.
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Eramo SL, Paciello F, et al. Curcuma longa (curcumin) decreases in vivo cisplatin-induced ototoxicity through heme oxygenase-1 induction. Otol Neurotol. 2014;35:169–177.
   Web of Science ®Google Scholar
• Paciello F, Fetoni AR, Mezzogori D, et al. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci Rep. 2020;10(1):1063.
   PubMed Web of Science ®Google Scholar
• Salt AN, Plontke S. Pharmacokinetic principles in the inner ear: influence of drug properties on intratympanic applications. Hear Res. 2018;368:28–40.
   PubMed Web of Science ®Google Scholar
• Lee JE, Nakagawa T, Kim TS, et al. A novel model for rapid induction of apoptosis in spiral ganglions of mice. Laryngoscope. 2003;113(6):994–999.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Kang H, Lee YY, et al. Cisplatin-induced ototoxicity in rats is driven by RIP3-dependent necroptosis. Cells. 2019;8(5):409.
   Web of Science ®Google Scholar
• Fernandez K, Wafa T, Fitzgerald TS, et al. An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity. Hear Res. 2019;375:66–74.
   PubMed Web of Science ®Google Scholar
• Gu J, Chen Y, Tong L, et al. Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects. J Nanobiotechnol. 2020;18(1):53.
   PubMed Web of Science ®Google Scholar
• Sergi B, Ferraresi A, Troiani D, et al. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res. 2003;182(1–2):56–64.
   PubMed Web of Science ®Google Scholar
• Sergi B, Fetoni AR, Ferraresi A, et al. The role of antioxidants in protection from ototoxic drugs. Acta Otolaryngol. 2004;124(Suppl 552):42–45.
   PubMed Web of Science ®Google Scholar
• Takimoto Y, Imai T, Kondo M, et al. Cisplatin-induced toxicity decreases the mouse vestibulo-ocular reflex. Toxicol Lett. 2016;262:49–54.
   PubMed Web of Science ®Google Scholar
• Giari L, Dezfuli BS, Astolfi L, et al. Ultrastructural effects of cisplatin on the inner ear and lateral line system of zebrafish (Danio rerio) larvae. J Appl Toxicol. 2012;32(4):293–299.
   PubMed Web of Science ®Google Scholar
• Todd DW, Philip RC, Niihori M, et al. A fully automated high-throughput zebrafish behavioral ototoxicity assay. Zebrafish. 2017;14(4):331–342.
   PubMed Web of Science ®Google Scholar
• Pang J, Xiong H, Zhan T, et al. Sirtuin 1 and autophagy attenuate cisplatin-induced hair cell death in the mouse cochlea and zebrafish lateral line. Front Cell Neurosci. 2018;12:515.
   PubMed Web of Science ®Google Scholar
• Ribak Lp Husain K, Morris C, et al. Effect of protective agents against cisplatin ototoxicity. Am J Otol. 2000;21:513–520.
   PubMedGoogle Scholar
• Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal. 2009;11(12):3013–3069.
   PubMed Web of Science ®Google Scholar
• Liu T, Zong S, Luo P, et al. Enhancing autophagy by down-regulating GSK-3β alleviates cisplatin-induced ototoxicity in vivo and in vitro. Toxicol Lett. 2019;313:11–18.
   PubMed Web of Science ®Google Scholar
• Nonnekens J, Hoeijmakers HG. After surviving cancer, what about late life effects of the cure? EMBO Mol Med. 2017;9(1):4–6.
   PubMed Web of Science ®Google Scholar
• Benkafadar N, Menardo J, Bourien J, et al. Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med. 2017;9(1):7–26.
   PubMed Web of Science ®Google Scholar
• Kalinec F, Kalinec G, Boukhvalova M, et al. Establishment and characterization of conditionally immortalized organ of corti cell lines. Cell Biol Int. 1999;23(3):175–184.
   PubMed Web of Science ®Google Scholar
• Kalinec GM, Webster P, Lim DJ, et al. Cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol Neurotol. 2003;8(4):177–189.
   PubMed Web of Science ®Google Scholar
• Rivolta MN, Grix N, Lawlor P, et al. Auditory hair cell precursors immortalized from the mammalian inner ear. Proc Biol Sci. 1998;265(1406):1595–1603.
   PubMed Web of Science ®Google Scholar
• Previati M, Lanzoni I, Astolfi L, et al. Cisplatin cytotoxicity in organ of corti-derived immortalized cells. J Cell Biochem. 2007;101(5):1185–1197.
   PubMed Web of Science ®Google Scholar
• Astolfi L, Simoni E, Ciorba A, et al. In vitro protective effects of Ginkgo biloba against cisplatin toxicity in mouse cell line OCk3. Audiol Med. 2008;6(4):251–258.
   Google Scholar
• Low WK, Kong SW, Tan MG. Ototoxicity from combined Cisplatin and radiation treatment: an in vitro study. Int J Otolaryngol. 2010;2010:1–29.
   Google Scholar
• Salehi P, Akinpelu OV, Waissbluth S, et al. Attenuation of cisplatin ototoxicity by otoprotective effects of nanoencapsulated curcumin and dexamethasone in a guinea pig model. Otol Neurotol. 2014;35:1131–1139.
   PubMed Web of Science ®Google Scholar
• Kaur T, Borse V, Sheth S, et al. Adenosine A1 receptor protects against cisplatin ototoxicity by suppressing the NOX3/STAT1 inflammatory pathway in the cochlea. J Neurosci. 2016;36(14):3962–3977.
   PubMed Web of Science ®Google Scholar
• Ma W, Hu J, Cheng Y, et al. Ginkgolide B protects against cisplatin-induced ototoxicity: enhancement of Akt-Nrf2-HO-1 signaling and reduction of NADPH oxidase. Cancer Chemother Pharmacol. 2015;75(5):949–959.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Park C, Lee JN, et al. Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins. Toxicol Appl Pharmacol. 2015;288(2):192–202.
   PubMed Web of Science ®Google Scholar
• Wang W, Shanmugam MK, Xiang P, et al. Sphingosine 1-phosphate receptor 2 induces otoprotective responses to Cisplatin treatment. Cancers. 2020;12(1):211.
   Web of Science ®Google Scholar
• Paken J, Govender CD, Pillay M, et al. A review of Cisplatin-associated ototoxicity. Semin Hear. 2019;40(2):108–121.
   PubMedGoogle Scholar
• Prasad KN, Bondy C. Increased oxidative stress, inflammation, and glutamate: potential preventive and therapeutic targets for hearing disorders. Mech Ageing Dev. 2020;185:111191.
   PubMed Web of Science ®Google Scholar
• Sheth S, Mukherjea D, Rybak LP, et al. Mechanisms of Cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 2017;11:338.
   PubMed Web of Science ®Google Scholar
• Santos NAGD, Ferreira RS, Santos ACD. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 2020;136:111079.
   PubMed Web of Science ®Google Scholar
• Poirrier AL, Van den Ackerveken P, Kim TS, et al. Ototoxic drugs: difference in sensitivity between mice and guinea pigs. Toxicol Lett. 2010;193(1):41–49.
   PubMed Web of Science ®Google Scholar
• Le Prell CG. Otoprotectants: from research to clinical application. Semin Hear. 2019;40(2):162–176.
   PubMedGoogle Scholar
• Yu D, Gu J, Chen Y, et al. Current strategies to combat Cisplatin-induced ototoxicity. Front Pharmacol. 2020;11:999.
   PubMed Web of Science ®Google Scholar
• Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology. 2003;45(3):380–393.
   PubMed Web of Science ®Google Scholar
• Waissbluth S. Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far? Eur Arch Otorhinolaryngol. 2020;277(9):2413–2422.
   PubMed Web of Science ®Google Scholar
• Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63–74.
   PubMed Web of Science ®Google Scholar
• Freyer DR, Brock PR, Chang KW, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health. 2020;4(2):141–150.
   PubMedGoogle Scholar
• U.S. National Library of Medicine. Aug 2020. http://www.clinicaltrials.gov
   Google Scholar
• Marshak T, Steiner M, Kaminer M, et al. Prevention of Cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg. 2014;150(6):983–990.
   PubMed Web of Science ®Google Scholar
• Yoo J, Hamilton SJ, Angel D, et al. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope. 2014;124:87–94.
   PubMed Web of Science ®Google Scholar
• Rolland V, Meyer F, Guitton MJ, et al. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. J Otolaryngol Head Neck Surg. 2019;48(1):4–10.
   PubMedGoogle Scholar
• Viglietta V, Shi F, Hu QY, et al. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. Invest New Drugs. 2020. DOI:10.1007/s10637-020-00918-1
   PubMed Web of Science ®Google Scholar
• Knight KR, Chen L, Freyer D, et al. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Cin Oncol. 2017;35(4):440–445.
   PubMed Web of Science ®Google Scholar